Shannon L. Devers, who serves as Executive Vice President and Chief Human Resources Officer at Ionis Pharmaceuticals (NASDAQ: IONS), recorded a sale of 6,193 shares of common stock on April 2, 2026, according to a Form 4 filing with the Securities and Exchange Commission.
The shares were sold at a weighted average price of $74.0535, producing total proceeds of $458,613. Reported prices for the individual sales in the filing ranged between $73.62 and $74.2450.
Following the completion of the sale, Devers' direct holdings in Ionis stand at 16,348 shares. The transaction was carried out under a pre-arranged Rule 10b5-1 trading plan that Devers adopted on November 24, 2025, the filing indicates.
Ionis shares are trading near $74.79, the filing notes, after a notable 160.5% increase in the stock over the last 12 months. An InvestingPro analysis referenced in the filing assigns the stock an "Overall Health" score of "Fair."
Separately, the company has announced a wholesale acquisition cost for its drug Tryngolza of $40,000 for the severe hypertriglyceridemia indication. That price point is materially higher than the $10,000 to $20,000 range the company previously guided, and it comes in below a competing therapy, Arrowhead’s Redemplo, which is priced at $60,000.
The updated pricing for Tryngolza has prompted responses from multiple analyst firms. Barclays increased its price target on Ionis shares from $95 to $106 while maintaining an Overweight rating. RBC Capital reiterated an Outperform rating with a $95 price target. BofA Securities maintained a Buy rating and a $100 price target. H.C. Wainwright reiterated a Buy rating and set a $120 price target following regulatory developments in Europe. William Blair also maintained an Outperform rating and highlighted the higher-than-expected pricing for Tryngolza compared with earlier estimates.
The SEC Form 4 filing provides the detailed transaction data for Devers' sale and the specifics of the 10b5-1 plan under which it was executed. The juxtaposition of insider selling, the company’s updated drug pricing, and the subsequent analyst moves offers multiple data points investors and market watchers may consider when assessing Ionis' near-term outlook.
Because the information in the filing and in company announcements is limited to the facts presented, the broader market implications and long-term effects of the pricing decision and the insider sale remain to be seen.